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Background: Histone deacetylase 3 (HDAC3) is overexpressed in cancers and its inhibition enhances anti-tumor
chemotherapy. ZBP-89, a transcription factor, can induce pro-apoptotic Bak and reduce HDAC3 but the mechanism
is unknown. Pin1, a molecular switch that determines the fate of phosphoproteins, is known to interact with
HDAC3. The aim of this study was to investigate the mechanism how ZBP-89 downregulated HDAC3.
Methods: In this study, liver cells, Pin1-knockout Pin1−/− and Pin1 wild-typed Pin+/+ cells were used to explore how
ZBP-89 reduced HDAC3. The overexpression of ZBP-89 was achieved by infecting cells with Ad-ZBP-89, an adenoviral
construct containing ZBP-89 gene. The role of NF-κB was determined using CAY10576, MG132 and SN50, the former
two being inhibitors of IκB degradation and SN50 being an inhibitor of p65/p50 translocation. A xenograft tumor
model was used to confirm the in vitro data.
Results: ZBP-89 reduced HDAC3, and it could form a complex with IκB and induce IκB phosphorylation to inhibit IκB.
Furthermore, ZBP-89-mediated HDAC3 reduction was suppressed by IκB degradation inhibitors CAY10576 and MG132
but not by p65/p50 translocation inhibitor SN50, indicating that IκB decrease rather than the elevated activity of NF-κB
contributed to HDAC3 reduction. ZBP-89-mediated HDAC3 or IκB reduction was significantly less obvious in Pin1−/−
cells compared with Pin1+/+ cells. In Ad-ZBP-89-infected Pin1+/+ cancer cells, Pin1 siRNA increased HDAC3 but
decreased Bak, compared with cells without ZBP-89 infection. These findings indicate that Pin1 participates in ZBP-89-
mediated HDAC3 downregulation and Bak upregulation. The cell culture result was confirmed by in vivo mouse tumor
model experiments.
Conclusions: ZBP-89 attenuates HDAC3 by increasing IκB degradation. Such attenuation is independent of NF-κB
activity but partially depends on Pin1. The novel pathway identified may help generate new anti-cancer strategy by
targeting HDAC3 and its related molecules.
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ZBP-89, a Kruppel-like zinc finger binding transcription
factor, binds GC-rich promoter elements to activate or
suppress gene expression. ZBP-89 regulated expression
can result in altered cell growth and death. Previously,
we found that ZBP-89 could bind to histone deacetylase
3 (HDAC3) protein to inhibit its deacetylation activity,
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HDAC3, a histone deacetylase enzyme, removes acetyl-
residues from histones and forms transcriptional co-
repressors with other proteins. HDAC3 can also act as a
non-histone deacetylase [3,4], playing an important role
in physiologic and pathological conditions, such as apop-
tosis, tumorigenesis and metastasis. The high expression
of HDAC3 has been documented in HCC and associated
with the reduced recurrence-free survival [5-7]. The inhib-
ition of HDAC3 can lead to a strong anti-tumoral effect,
which enhances the efficacy of chemotherapeutic agents
in HCC [5,7]. Furthermore, the increase in HDAC3 may
contribute to the hapatocarcinogenesis [6].is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Ye et al. Journal of Translational Medicine  (2015) 13:23 Page 2 of 10Peptidyl-prolyl cis/trans isomerase 1 (Pin1), a highly
conserved enzyme, specifically phosphorylates Ser/Thr-
Pro to control the fates of phospho-proteins [8]. For
example, Pin1 can regulate the phosphorylation or de-
phosphorylation of proteins to prevent or enhance pro-
tein degradation and thus control diverse cellular
processes including tumorigenesis. In HCC, Pin1 can
form a complex with hepatitis B virus x protein (HBx), a
well-known hepatocarcinogenetic factor, and overexpress
in cancer tissues, indicating that Pin1 may promote hepa-
tocarcinogenesis [9-12].
It has been shown that HDAC3 can be the substrate of
Pin1 and 14-3-3 proteins [13]. 14-3-3, a family of con-
served regulatory molecules in the regulation of mito-
genic signal transduction, apoptotic cell death, and cell
cycle, can protect HDAC3 form degradation, whereas
Pin1 promotes HDAC3 degradation [13]. Therefore, the
level of HDAC3 is regulated by competition between
Pin1 and 14-3-3 proteins. Our previous study has shown
that ZBP-89 could bind to HDAC3 protein to inhibit its
deacetylation activity in HCC [2]. Thus it appears that
HDAC3 is subjected to the control by both ZBP-89 and
Pin1. Interestingly, the functions of both ZBP-89 and
Pin1 are closely associated with NF-κB, as Pin1 can
stabilize the NF-κB subunit p65 to enhance its activity
and ZBP-89 can compete with NF-κB to bind to the pro-
moter of certain genes such as MMP-3 [14-18]. We
therefore hypothesize that NF-κB may play a role in the
regulation of HDAC3 by ZBP-89 and Pin1 in HCC. The
current study investigated the mechanism how ZBP-89
downregulated HDAC3 in HCC.
Methods
Cell lines, chemicals and reagents
The human HCC cell lines PLC/PRF/5 and HepG2 were
obtained from American Type Culture Collection (Rockville,
MD). Pin1-knockout cell line Pin1−/− and wild-type Pin1+/+
cell line were a generous gift from Dr. Zi-Gang Dong
(The Hormel Institute, University of Minnesota, MN)
[19]. Pin1−/− cells, derived from mouse embryo fibroblasts
(MEFs), were originally generated from Pin1 knockout
mice [20,21]. PLC/PRF/5, immortalized non-tumorigenic
human hepatocyte cell line MIHA, Pin1−/− and Pin1+/+
were maintained in Dulbecco’s modified Eagle medium
(Invitrogen, Carlsbad, CA), and HepG2 was maintained
in Minimum Essential Medium (Invitrogen, Carlsbad,
CA). CAY10576, MG132, HDAC3 and HDAC4 anti-
bodies were purchased from Cayman Chemical (Ann
Arbor, MI). NF-κB inhibitory peptide SN50 was form
Calbiochem (Darmstadt, Germany). Antibodies against
ZBP-89, p65 and Pin1 were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). Phospho-HDAC3 (Ser424)
and phospho-IκBα (Ser32/36) antibodies was from Cell Sig-
naling Technology (Beverly, MA). Ad-ZBP-89 viral vectorwas a generous gift from Dr. JL Merchant (University of
Michigan, MI).
Transfection of siRNA plasmid
The experiment was performed according to the previ-
ous publication [1]. Briefly, 3 × 105 cells were seeded in
6-well plates 1 day prior to transfection. Pin1 siRNA se-
quence was constructed into mU6 siRNA vector which
was a generous gift from Dr. Guoliang Huang (Guangdong
Medical College, Guangdong, China). mU6-siPin1 or
mU6-siControl plasmid was transfected into cells with
Fugene reagent (Roche, Indianapolis, IN). Two days later,
cells were lysed in RIPA buffer on ice with protease
inhibitors.
Cytosolic and nuclear extracts preparation
A nuclear extraction kit (Panomics, Fremont, CA) was
used to isolate nuclear and cytoplasmic fractions and it
was done according to our previous publication [22]. For
details, please refer to Additional file 1. The isolated
nuclear and cytoplasmic fractions were confirmed by
Western blot using anti-actin and lamin B antibodies re-
spectively (Figure 1c).
Co-immunoprecipitation (Co-IP) and western blot
Co-IP was carried out according to the previous report
with some modification [23]. Briefly, cell lysates were
precleared with protein A/G Plus-agarose beads at 4°C
for 4 h. Meanwhile, the primary antibody was coupled
with Dynabeads Protein G beads (Invitrogen, Carlsbad,
CA) at room temperature for 30 min. The precleard cell
lysates were incubated with beads-coupled primary anti-
body overnight at 4°C. The antibody-antigen immuno-
complex was collected though magnetic separation and
washed with PBS for three times. Immunocomplexes
were released by boiling in 2 × SDS sample buffer. 10%
SDS-PAGE gels were used and proteins were transferred
onto Hybond membranes (GE Healthcare, Arlington
Heights, IL) by electroblotting at 100 V for 2 h. After
blocking with 5% nonfat milk, the membrane was incu-
bated with the designated primary antibody for 2 h,
followed by incubation with a HRP-conjugated second-
ary antibody for 1 h. The signal was visualized by ECL
reagent.
Reverse transcription and real-time PCR
Total mRNA was extracted by a commercial mRNA ex-
traction kit (Invitrogen, Carlsbad, CA ). 2 μg of RNA
were reverse-transcripted into cDNA using oligo dT
primers. Real-time PCR primers for HDAC3 were syn-
thesized by Invitrogen. Forward primer: GCTGGAGGG
AAAAGGAGTGG; Reverse primer: GGCCTTGGGAG
AGAGAGGAA. PCR was carried out at 94°C for 30 s,
55°C for 30 s and 72°C for 45 s for 30 cycles, using ABI
Figure 1 Reduction of HDAC3 by ZBP-89. The ectopic expression of ZBP-89 attenuated HDAC3 protein expression but not HDAC4 in MIHA,
PLC/PRF/5 and HepG2 cells. The level of HDAC3 was decreased in a dose-dependent manner by ZBP-89 (a). Cell lysate was obtained to separate
the cytoplasmic and nuclear fractions. The reduction of HDAC3 and pHDAC3 proteins mainly occurred in the nucleus (b). The cytoplasmic and
nuclear fractions were verified using anti-actin and anti-lamin B antibodies respectively (c). RT-PCR analysis showed that the level of HDAC3 mRNA
was not changed by ZBP-89 ectopic expression (d). All experiments replicated at least three times.
Ye et al. Journal of Translational Medicine  (2015) 13:23 Page 3 of 10prism 7700 sequence detector and software to analyze
the data (Applied Biosystems, CA).
Immunohistochemistry and immunofluorescence
The tissue sections were blocked with SuperBlock buffer
(Thermo, IL) for 30 min, then incubated with a primary
antibody overnight at 4°C, followed by incubation with a
HRP-labeled IgG secondary antibody with three washes
in interval. The antigen-antibody complex was visualizedby the diaminobenzidine method. PBS that replaced the
primary antibody was used as a negative control. For im-
munofluorescent staining, cells were seeded on the
Millicell EZ SLIDE (Millipore, MA) and incubated over-
night. After treatments, the cells were fixed with 4%
paraformaldehyde for 10 min, followed by washing in
0.1% Triton X-100 with shaking for 10 min and then
blocking with 2% BSA for 30 min. The primary anti-
body was diluted with 2% BSA and incubated with cells
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Rhodamine-labeled secondary antibody for 1 h. Finally,
Prolong Gold antifade reagent (Invitrogen, Carlsbad,
CA) with DAPI stained the cells for 5 min. Fluorescent
cells were visualized using the Zeiss Axioplan 2 micro-
scope (Zeiss, Germany).
Xenograft animal model
The xenograft tumor model was generated by injecting
2 × 106 PLC/PRF/5 cells into the left axilla nude mice for
three weeks. Tumor-bearing mice were randomly di-
vided into two groups, 10 mice per group. The mice in
the therapeutic group were injected with ZBP-89 viral
expression vector (1 × 1010 pfu) into tumor tissues, while
the mice in the control group received saline injection.
The first injection was done at the first day when tumor-
bearing mice were divided into two groups, and the sec-
ond injection was done at 7 days later. Two weeks after
the 2nd injection, the tumors were excised intact and
weighted. Tumor tissues were subjected to H&E staining
and immunohistochemical staining. The tissue lysate
was analyzed by Western blot to detect ZBP-89, HDAC3
and Bak expression. The welfare and experiment proto-
col of these mice were strictly followed according to the
guidelines approved by the Animal Experimentation Eth-
ics Committee of our institute.
Statistical analysis
Analyses were performed using the Statistics Package for
Social Sciences (SPSS for Windows, version 13.0, SPSS).
One-way ANOVA was used to compare means of three
or more samples. t-test or paired t test was used to com-
pare the means of two variables. P values of less than
0.05 were considered statistically significant.
Results
The ectopic expression of ZBP-89 diminished HDAC3 but
not HDAC4 expression
We found that ZBP-89 inhibited the expression of HDAC3
and pHDAC3 proteins but not HDAC4 (Figure 1a), con-
firming our previous finding [2]. ZBP-89 also did not
affect the expression of pHDAC4 protein (Additional file 1:
Figure S1). In this study, we further examined if ZBP-89
could change subcellular distribution of HDAC3. After
different dose- and time-exposures to ZBP-89, cytosol and
nuclear extracts were respectively collected and subjected
to Western blot. Results indicated that the decrease of
HDAC3 and pHDAC3 proteins mainly occurred in the
nucleus (Figure 1b). We further found that ZBP-89 did
not change the level of HDAC3 mRNA as evident by RT-
PCR analysis (Figure 1d), suggesting that ZBP-89 down-
regulates HDAC3 at the post-translational instead of
transcriptional level.Knockdown of Pin1 greatly blocked ZBP-89-mediated
HDAC3 reduction
To study the role of Pin1 in the ZBP-89-mediated
HDAC3 reduction, two approaches were used. Firstly,
we examined the expression of HDAC3 in Pin1 allele-
knockout JB6 C141 Pin1−/− and Pin1 wild-type cell lines
JB6 C141 Pin1+/+, and found that the reduction of
HDAC3 by ZBP-89 was much more obvious in Pin1+/+
cells than in Pin1−/− cells (Figures 2a and 2b), suggesting
that ZBP-89-mediated HDAC3 reduction is partially but
not totally dependent on the presence of Pin1. It also
showed that Pin1−/− cells had higher levels of HDAC3
and pHDAC3 than that in Pin1+/+ cells. Secondly, we
used Pin1 siRNA to block the expression of Pin1 and
then examined HDAC3 expression in MIHA and PLC/
PFR/5 cells. Pin1 knockdown increased the levels of
HDAC3 and pHDAC3 (Figures 2c and d). Further exper-
iments showed that the block of Pin1 expression sup-
pressed ZBP-89-mediated HDAC3 reduction in both
cells (Figure 2e). Accompanied with the attenuation of
ZBP-89-mediated HDAC3 reduction, ZBP-89-induced Bak
was inhibited (Figure 2e). Finally, the co-IP experiment
showed that Pin1 was able to bind to HDAC3 (Figure 2f),
suggesting that Pin1 may directly interact with HDAC3.
ZBP-89 reduced the level of IκB
To examine the role of IκB, an endogenous inhibitor of
NF-κB, in the ZBP-89-mediated HDAC3 reduction,
Western blot was used to determine the level of IκB in
cells treated with Ad-ZBP-89. It was found that the ec-
topic expression of ZBP-89 reduced IκB protein in both
Pin1+/+ and Pin1−/− cells (Figure 3a). However, the reduc-
tion was much greater in Pin1+/+ cells than in Pin1−/− cells
as the ratio of the reduction is significantly lower in the
former than in the latter (Figure 3b). This finding indicates
that ZBP-89-induced reduction of IκB is partially associ-
ated with the presence of Pin1.
IκB degradation inhibitors suppressed ZBP-89-meditaed
HDAC3 reduction
To explore how IκB was reduced by ZBP-89 and partici-
pated in the reduction of HDAC3, three different NF-κB
inhibitors were employed to treat cells and the level of
pIκB was determined. It is known that IκB phosphoryl-
ation can lead to the degradation of IκB [24]. CAY10576
is a selective inhibitor of IKK-ε whose activation can lead
to the degradation of IκB and thus the activation of NF-
κB [25]. MG132, a proteasome inhibitor, can block the
activation of NF-κB through preventing proteasome-
mediated degradation of IκB [24]. SN50 is a specific
inhibitor of p50/p65 nuclear translocation and transcrip-
tional activity but does not interfere with IκB degradation
[26,27]. Results showed that pretreatment with CAY10576
inhibited ZBP-89-mediated induction of pIκB in MIHA,
Figure 2 Knockdown of Pin1 expression inhibited ZBP-89-mediated reduction of HDAC3. Pin1 allele-knockout Pin1−/− and Pin1+/+ cells
were infected with Ad-ZBP89 and the levels of HDAC and pHDAC were examined by Western blot (a), The densities of protein bands were
determined and the ratio of test (HDAC) to the control (actin) was calculated (b). This ratio was significantly lower in Pin1+/+ cells than in Pin1−/−
cells. Pin1+/+ represents Pin1+/+ MEFs, and Pin1−/− represents Pin1−/− MEFs. Cells were treated with Pin1 siRNA to inhibit Pin1 expression. The
inhibition of Pin1 expression increased the levels of HDAC3 and pHDAC3 in PLC/PRF/5 cells (c). The densities of protein bands were determined
to quantitate the protein levels (d). MIHA and PLC/PRF/5 cells were pretreated with Pin1 siRNA before Ad-ZBP-89 infection. Pin1 inhibition
significantly inhibited ZBP-89-mediated reduction of HDAC3 (e). The up-regulated expression of Bak by ZBP-89 was also markedly suppressed by Pin1
siRNA (e). Co-IP experiments showed that Pin1 bound to HDAC3 in PLC/PRF/5 cells (f). All experiments replicated at least three times. *p < 0.05,
**p < 0.01 paired t test, compared with respective controls.
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Similar results were obtained when the proteasome inhibi-
tor MG132 was used. SN50 inhibited NF-κB but did not
affect the level of pIκB (Figures 4c and e). Nevertheless,
similar to SN50, both CAY10576 and MG132 couldinhibit ZBP-89-mediated p65/50 (data not shown). How-
ever, importantly the ZBP-89-mediated HDAC3 reduction
could be prevented by CAY10576 or MG132 (Figures 4a
and b), but not by SN50 (Figure 4c). Therefore, these data
appear to suggest that the changes in IκB or pIκB rather
Figure 3 ZBP-89 stimulated IκB phosphorylation to decrease HDAC3. Cells were infected with Ad-ZBP-89. Total protein was isolated and
subjected to Western blot analysis of IκB and HDAC3 (a). ZBP-89 reduced the level of IκB in a dose-dependent manner in HCC cells. The densities
of IκB protein band were determined and the ratio of test (IκB) to the control (actin) was calculated (b). This ratio was significantly lower in
Pin1+/+ cells than in Pin1−/− cells (*p < 0.05, **p < 0.01, paired t test, compared with respective controls.
Ye et al. Journal of Translational Medicine  (2015) 13:23 Page 6 of 10than the activity of NF-κB are involved in ZBP-89-
mediated HDAC3 reduction. Using co-IP and Western
blot analysis, we testified that both IκB and pIκB were able
to bind to HDAC3 (Figure 4f), suggesting a direct inter-
action between both proteins in HCC cells.
ZBP-89 decreased HDAC3 but increased Bak in xenograft
tumor tissues
A nude mouse tumor model was established by subcuta-
neous injection of PLC/PRF/5 cells. The immunohisto-
chemical staining of tumor tissues showed that the
positive staining of HDAC3 in Ad-ZBP-89 group was
less than that in the saline group. We randomly counted
the positive-stained cells in 7 fields in each section, the
statistical analysis revealed that the expression of
HDAC3 was significantly decreased in mice treated with
Ad-ZBP-89 compared with those treated with saline
(Figures 5a and b). The immunohistochemical result was
confirmed by Western blot analysis, as the level of
HDAC3 protein was lower in mice treated with Ad-
ZBP-89 than those treated with saline (Figures 5c and
d), but HDAC4 level did not show obvious difference
(data not shown). Our data also confirmed that ZBP-89
could significantly increase the level of Bak (Figure 5c
and d).
Discussion
In this study, we first confirmed our previous finding
that ZBP-89 reduced both HDAC3 and pHDAC3 pro-
teins in HCC cells [2]. The level of HDAC3 is frequently
increased in HCC [5-7], suggesting a possible role of
HDAC3 in hepatocarcinogenesis. Indeed, the increased
expression of HDAC3 is significantly correlated with
DNA copy number gains in HCC [5], and HDAC3 acts
on miR-224-residing locus in Xq28 to increase the level
of miR-224, one of the most commonly up-regulated
microRNAs in HCC [6]. The positive role of HDAC3 in
the growth and progression of HCC is further supportedby the inhibitory experiment, in which the downregula-
tion of HDAC3 results in a strong anti-tumor effect and
enhances the efficacy of chemotherapeutic agents in
HCC [5-7]. HDAC3 may also serve as a biomarker for
HCC recurrence as the high expression level of HDAC3
is associated with the reduced recurrence-free survival
of HCC patients [7]. Although HDAC3 participates in
the development, progression, treatment and survival of
HCC, the molecular mechanism leading to its increase
in HCC is unknown. ZBP-89 is known as an apoptotic
inducer in HCC and studies have demonstrated that
ZBP-89 can enhance the pro-apoptotic Bak [1.2]. It is
not surprising to find that ZBP-89 is able to reduce
HDAC3 since there is evidence showing that the function
of ZBP-89 is related to epigenetic events. For example,
ZBP-89-induced p21waf1 activation can be enhanced by
HDAC inhibitor sodium butyrate [28]. ZBP-89 and
HDAC3 can form a complex to help HDAC3 bind to the
p16 promoter, resulting in p16 downregulation [29].
It appears that there are some connections between
HDAC3 and NF-κB or its subunits. NF-κB subunit p65
has been shown to recruit HDAC3 to the antioxidant re-
sponse element of Nrf2 gene, leading to local histone
hypoacetylation [30]. The activity of NF-κB is associated
with the nuclear export of HDAC3, and HDAC3 can
efficiently inhibit CREB3-induced NF-κB activation
[31,32]. The activation of NF-κB by IκB phosphorylation
is accompanied with the reduction in HDAC levels/ac-
tivity [33]. IκBα is known to bind HDAC3 through its
ANKYRIN amino acid repeats [34]. We therefore wonder
whether NF-κB or its subunits contribute to ZBP-89-
induced the reduction of HDAC3 in HCC. To address this
question, we first demonstrated that accompanied with
the reduction of HDAC3, ZBP-89 could enhance IκB
phosphorylation to reduce the level of IκB in HCC. We
further showed that ZBP-89 could form a complex with
either IκB or pIκB, suggesting a possible direct interaction
between them. These findings appear to imply that ZBP-
Figure 4 ZBP-89 reduced HDAC3 via stimulating IκB phosphorylation. After cells were infected with Ad-ZBP-89, they were treated with
CAY10576, MG132 and SN50. After the treatment, total protein was isolated and subjected to Western blot analysis for pIκB and HDAC3. Either
CAY10576 or MG132 inhibited pIκB as well as HDAC3 in MIHA, PLC/PRF/5 and Pin1+/+ and Pin1−/− cells (a and b). p65/p50 inhibitory peptide
SN50 suppressed NF-κB activity (e) but had no effect on pIκB (c). The level of ZBP-89 mediated HDAC3 reduction was also not affected by SN50
(c). CAY10576 did not affect the level of total IκB (d). Co-IP and Western blot were employed to test if IκB and pIκB could bind to HDAC3. IκB
and pIκB were both detected in the immunoprecipitated HDAC3 complex, indicating that HDAC3 can form a complex with IκB, as well as pIκB (f).
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ylation (pIκB) to activate NF-κB, which may lead to the
reduction of HDAC3. To verify this assumption, we
employed three different inhibitors to block NF-κBactivity. CAY10576 and MG132 can prevent the degrad-
ation of IκB to block the activation of NF-κB [24,25].
SN50 inhibits p50/p65 nuclear translocation rather than
IκB degradation to block the activation of NF-κB [26,27].
Figure 5 ZBP-89 decreased HDAC3 but increased Bak in xenograft tumor tissue. Ad-ZBP-89 infection effectively enhanced ZBP-89 levels in
10 tumor-bearing mice. The expression of HDAC3 in xenograft tumor tissues was examined by both immunohistochemical staining and Western
blotting analysis (a and c). The positive-stained cells were counted and the density of Western blot bands was determined (b and d). Both
methods showed that ZBP-89 overexpression significantly reduced HDAC3 expression, compared with saline controls (*p < 0.05, b and d). The
ectopic expression of ZBP-89 also significantly increased Bak expression (*p < 0.05, d). **p < 0.01, compared with saline controls.
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the activation of NF-κB, ZBP-89-mediated HDAC3 re-
duction can be prevented by CAY10576 or MG132
only, but not by SN50. Therefore, the decrease of IκB
or the increase pIκB rather than the elevated activity of
NF-κB contributes to ZBP-89-mediated HDAC3 reduc-
tion in HCC.
To further explore the relevant mechanism of ZBP-89-
mediated the reduction of HDAC3, we studied the role
of Pin1 in this pathway since Pin1 can bind to HDAC3
to cause HDAC3 degradation [13], and Pin1 is overex-
pressed in HCC [9-12]. We found that the inhibition of
Pin1 increased the level of IκB and that Pin1-knocked-
out cells Pin1−/− possessed higher levels of HDAC3 and
pHDAC3 than cells with Pin1 wild-type cells Pin1+/+, in-
dicating that Pin1 may negatively regulate HDAC3 via
decreasing the level of IκB. We further demonstrated
that the downregulation of Pin1 significantly, though not
completely, inhibited ZBP-89-mediated HDAC3 decrease.
The similar results were also found in Pin1−/− and Pin1+/+
cells. The inhibitory effect of ZBP-89 on HDAC3 was
much stronger in the Pin1+/+ cells than in Pin1−/− cells.
These findings suggest that ZBP-89-mediated HDAC3reduction is partially dependent on the Pin1 protein whose
level is negatively associated with IκB. Therefore, Pin1 is
required for the maximal effect of ZBP-89 on HDAC3
reduction.
Our study suggests that ZBP-89-mediated HDAC3 re-
duction likely contributes to its ability to increase pro-
apoptotic molecule Bak in HCC cells. First, when cells
were treated with ZBP-89, the level of HDAC3 protein
was negatively associated with the expression of Bak
protein in cell culture experiments. Second, the inhib-
ition of Pin by siRNA resulted in the increase of HDAC3
but the decrease of Bak in the presence of ZBP-89.
Third, in the mouse model of HCC, ZBP-89 treatment
led to the reduction of HDAC3 but the increase of Bak.
The close association between HDAC3 and Bak in ZBP-
89-treated cells is in line with the finding that the inhib-
ition of HDAC3 leads to the increase of Bak [35].
Conclusions
The study demonstrates that ZBP-89-mediated reduction
of HDAC3 is partially dependent on the phosphorylation
of IκB and the presence of Pin1, but is independent of NF-
κB activity. The reduction of HDAC3 likely contributes to
Ye et al. Journal of Translational Medicine  (2015) 13:23 Page 9 of 10ZBP-89-induced increase of Bak. The novel pathway iden-
tified herein may open up a new field to inhibit HCC by
the application of ZBP-89 and the inhibition of HDAC3.
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